GSK: Result Summaries: Compounds > cilomilast

Home > Result Summaries: Compounds > cilomilast

Result Summaries: cilomilast

Result Summaries for cilomilast
GSK Study ID	Phase	Title	Summary (Download)
207499/039	Phase 3	A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of Cilomilast (15mg Twice Daily) in Patients with Chronic Obstructive Pulmonary Disease (COPD). (0 citation(s))
207499/040	Phase 3	A Multicentre, Open-label Extension Study to Evaluate the Safety, Tolerability and Efficacy of Oral SB-207499 (15 mg twice daily) in Patients with Chronic Obstructive Pulmonary Disease (COPD). (0 citation(s))
207499/041	Phase 3	A Multicenter Open-label Extension Study to Evaluate the Safety, Tolerability and Efficacy of Oral Cilomilast (15 mg twice daily) in Patients with Chronic Obstructive Pulmonary Disease (COPD) (0 citation(s))
207499/042	Phase 3	A Randomized, 24-Week, Double-blind, Placebo-controlled, Parallel-Group Study to Evaluate the Efficacy, Safety and Tolerability of Cilomilast (15mg Twice Daily) in Patients with Chronic Obstructive Pulmonary Disease (COPD). (0 citation(s))
207499/076	Phase 3	A 12-week, Multicentre, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Anti-inflammatory Activity of SB207499 15 mg Twice Daily in Patients With Chronic Obstructive Pulmonary Disease (COPD) (0 citation(s))
207499/091	Phase 3	A Randomized, 24-Week, Double-blind, Placebo-controlled, Parallel-Group Study Followed by a 2-Week, Randomized, Double-blind, Run-out Phase to Evaluate the Efficacy, Safety, Tolerability and Discontinuation of SB207499 (15mg Twice Daily) in Patients with Chronic Obstructive Pulmonary Disease (COPD). (0 citation(s))
207499/110	Phase 3	A 12-week, Multicenter, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Anti-inflammatory Activity of Cilomilast 15 mg Twice Daily in Patients With Chronic Obstructive Pulmonary Disease (COPD) (0 citation(s))
207499/111	Phase 3	A 12-week, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Effect of Cilomilast (15 mg Twice Daily) on Trapped Gas Volume in Patients With Chronic Obstructive Pulmonary Disease (0 citation(s))
207499/121	Phase 3	A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of cilomilast (15mg BID) in Patients with Chronic Obstructive Pulmonary Disease (COPD). (0 citation(s))
207499/156	Phase 3	A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of Cilomilast (15mg BID) in Patients with Chronic Obstructive Pulmonary Disease (COPD). (0 citation(s))
207499/157	Phase 3	A Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of Oral Cilomilast (15 mg bd) When Given as Maintenance Treatment for 12 Months to Subjects with Chronic Obstructive Pulmonary Disease (COPD) (0 citation(s))
207499/168	Phase 3	A Randomized, 12-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Tolerability of Cilomilast 15mg Twice Daily in Patients with Chronic Obstructive Pulmonary Disease (COPD) (0 citation(s))
207499/180	Phase 3	An 18-week randomized, double-blind, placebo-controlled, multicenter study designed to compare treatment with cilomilast to that with placebo for changes in ventilatory mechanics and function (both at rest and during exercise), as well as related exertional dyspnea and exercise performance, in hyperinflated p (0 citation(s))
207499/181	Phase 3	A 13-week randomised, double-blind, parallel group, mulitcentre study to compare the bronchial anti-inflammatory activity of oral cilomilast (15 mg bd) with placebo twice daily in subjects with Chronic Obstructive Pulmonary Disease (COPD) (0 citation(s))
CIL103657	Phase 3	A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients with Chronic Obstructive Pulmonary Disease (COPD) (0 citation(s))

Filter list by: